Healthcare / BiotechnologyTaipei Exchange
$12.10
+0.05 (+0.41%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 17%
FCF escenarios
weak_data · normalized FCF $-36.4M · quality 38.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
20/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.2B
P/E
N/A
•EV/EBITDA
23.9x
↑ROE
-6.5%
↓Gross Margin
42.9%
↓Debt/Equity
0.90
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+37.8%
FCF CAGR
—
FCF margin
17.9%
FCF / Net income
-1.04x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $471.8M · net income $-81.5M · FCF $84.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $471.8M | $471.8M | $366.4M | $234.3M | $180.1M |
| Net Income | $-81.5M | $-81.5M | $-94.7M | $-125.3M | $-102.1M |
| EBITDA | $89.6M | $89.6M | $-6.8M | $-92.6M | $-70.1M |
| EPS | — | — | -1.19 | -1.99 | -1.63 |
| Gross Margin | 42.9% | 42.9% | 52.9% | 59.3% | 52.6% |
| Operating Margin | -10.0% | -10.0% | -23.7% | -50.6% | -61.3% |
| Net Margin | -17.3% | -17.3% | -25.8% | -53.5% | -56.7% |
| Balance Sheet | |||||
| Debt/Equity | 0.90 | 0.90 | 0.78 | 0.05 | 0.10 |
| Current Ratio | 1.90 | 1.90 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $84.6M | $84.6M | $-382.3M | $-36.4M | $-45.6M |
| Returns | |||||
| ROE | -6.5% | -6.5% | -7.9% | -18.9% | -21.7% |
| Valuation | |||||
| EV/EBITDA | 23.86 | 23.86 | — | — | — |
| P/B | 0.89 | 0.89 | 1.77 | 3.70 | — |
| Growth & Yield | |||||
| Revenue Growth | 28.7% | 28.7% | 56.4% | 30.1% | — |
| EPS Growth | — | — | 40.2% | -22.1% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-19.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.19 → n/d
Residual
-19.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.